Interim results for the six months ended 30 June 2022
Significant strategic and operational progress towards becoming a global viral vector leader Oxford, UK – 15 September 2022: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading…